藥碼
BOT02
藥名
Botox 健保 針 1 U
英文商品名
Botox 健保 針 1 U
中文商品名
保妥適乾粉注射劑
螢幕名
事審 Botox 健保 針 1 U
劑型
Inj
規格
Botulinum toxin type A 1 Units
成分
藥理分類
Other Misc. Therapeutic Agents
健保碼
KC00525299
ATC碼
適應症
Blepharospasm
Cervical dystonia
Spasticity
Cervical dystonia
Spasticity
藥理
Neuromuscular Blocker Agent, Toxin; Ophthalmic Agent, Toxin
藥動學
禁忌症
Hypersensitivity to any botulinum toxin preparation or any component of the formulation; infection at the proposed injection site(s).
懷孕分類
Adverse events have been observed in animal reproduction studies.
哺乳分類
It is not known if it is present in breast milk. According to the manufacturer, therapy should take into account the risk of infant exposure.
副作用
Bladder dysfunction:Urinary tract infection, bacteriuria, urinary retention.
Central nervous system: Headache
Gastrointestinal: Dysphagia
Neuromuscular & skeletal: Neck pain
Respiratory: Upper respiratory tract infection
Ophthalmic: Blepharoptosis, vertical deviation of eyes
Central nervous system: Headache
Gastrointestinal: Dysphagia
Neuromuscular & skeletal: Neck pain
Respiratory: Upper respiratory tract infection
Ophthalmic: Blepharoptosis, vertical deviation of eyes
劑量和給藥方法
Blepharospasm: IM
Initial dose: 1.25 to 2.5 units injected into the medial and lateral pretarsal orbicularis oculi of the upper lid and lateral pretarsal orbicularis oculi of lower lid.
Dose may be increased up to twice the previous dose if the response from the initial dose lasted ?2 months; maximum dose per site: 5 units. Cervical dystonia: IM
For dosing guidance, the mean dose is 236 units divided among the affected muscles in patients previously treated with botulinum toxin (maximum: ?50 units/site). Spasticity: IM
Individualize dose based on patient size, extent, and location of muscle involvement, degree of spasticity, local muscle weakness, and response to prior treatment.
Initial dose: 1.25 to 2.5 units injected into the medial and lateral pretarsal orbicularis oculi of the upper lid and lateral pretarsal orbicularis oculi of lower lid.
Dose may be increased up to twice the previous dose if the response from the initial dose lasted ?2 months; maximum dose per site: 5 units. Cervical dystonia: IM
For dosing guidance, the mean dose is 236 units divided among the affected muscles in patients previously treated with botulinum toxin (maximum: ?50 units/site). Spasticity: IM
Individualize dose based on patient size, extent, and location of muscle involvement, degree of spasticity, local muscle weakness, and response to prior treatment.
小兒調整劑量
Blepharospasm/strabismus
Children ?12 years: Refer to adult dosing. Cervical dystonia
Children ?16 years: Refer to adult dosing. Spasticity (cerebral palsy related [dynamic equinus foot deformity])
Children ?2 years: IM: 4 units/kg (total dose) divided into two injections into medial and lateral heads of the gastrocnemius of affected leg; if clinically indicated, may repeat every 2 months (maximum dose: 200 units).
In diplegia, the recommended dose is 6 units/kg (total dose) divided between affected limbs.
Children ?12 years: Refer to adult dosing. Cervical dystonia
Children ?16 years: Refer to adult dosing. Spasticity (cerebral palsy related [dynamic equinus foot deformity])
Children ?2 years: IM: 4 units/kg (total dose) divided into two injections into medial and lateral heads of the gastrocnemius of affected leg; if clinically indicated, may repeat every 2 months (maximum dose: 200 units).
In diplegia, the recommended dose is 6 units/kg (total dose) divided between affected limbs.
腎功能調整劑量
There are no dosage adjustments provided in the manufacturer's labeling.
肝功能調整劑量
There are no dosage adjustments provided in the manufacturer's labeling.
安定性
藥袋資訊
臨床用途
肉毒桿菌製劑
主要副作用
泡製方法
儲存方式
請置於 2-8℃ 冷藏儲存
注意事項
其他說明
門診 <健保且非單位常備專用藥碼> 藥庫 冰X11
藥品外觀
顏色
形狀
剝痕
標記1
標記2
其他
健保藥價
63
自費價
83.79
仿單
資料庫
健保給付規定